MaxCyte, Inc. Debt Securities, Available-for-sale, Amortized Cost
MaxCyte, Inc. (MXCT) had Debt Securities, Available-for-sale, Amortized Cost of $241.47 million as of 2022-03-31, per its 10-Q filed 2022-05-09.
Discontinued › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2022-05-09
- 2022-03-31: Debt Securities, Available-for-sale, Amortized Cost $241.47M.
- 2021-12-31: Debt Securities, Available-for-sale, Amortized Cost $252.10M.
- 2021-09-30: Debt Securities, Available-for-sale, Amortized Cost $253.56M.
- 2021-06-30: Debt Securities, Available-for-sale, Amortized Cost $70.24M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2022-03-31 | $241.47M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $252.10M 10-Q · filed 2022-05-09 |
| 2021-09-30 | $253.56M 10-Q · filed 2021-11-10 |
| 2021-06-30 | $70.24M 10-Q · filed 2021-09-13 |
| 2020-12-31 | $31.23M 10-K · filed 2022-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |